Collaborative and Licensing Arrangements - Schedule of Funding Expenses (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2025 |
Jun. 30, 2024 |
Jun. 30, 2025 |
Jun. 30, 2024 |
|
| Research and Development Arrangement, Contract to Perform for Others | ||||
| Research and development expense | $ 524,896 | $ 454,466 | $ 1,006,783 | $ 915,104 |
| Amgen, Inc | ||||
| Research and Development Arrangement, Contract to Perform for Others | ||||
| BeOne’s portion of the development funding | 52,196 | 44,385 | 92,715 | 71,005 |
| Less: Amortization of research and development cost share liability | 25,757 | 21,903 | 45,569 | 35,039 |
| Research and development expense | 26,439 | $ 22,482 | 47,146 | $ 35,966 |
| Remaining portion of development funding cap | $ 242,916 | $ 242,916 | ||
| X | ||||||||||
- Definition Amortization Of Financing Commitment No definition available.
|
| X | ||||||||||
- Definition Financing Commitment Expenses No definition available.
|
| X | ||||||||||
- Definition Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|